Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02636036 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
A Phase 1 study of Colorectal Cancer and Squamous Cell Carcinoma of the Head and Neck, sponsored by Akamis Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 6
- Study locations
NCT02636036 is a Phase 1 study of Colorectal Cancer and Squamous Cell Carcinoma of the Head and Neck that has completed, run by Akamis Bio. The registered enrollment target is 51 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT02636036, a Phase 1 study of Colorectal Cancer and Squamous Cell Carcinoma of the Head and Neck, has completed, sponsored by Akamis Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, SCCHN, escalation phase), not responding to standard therapy.
Conditions Studied
Interventions
- BIOLOGICAL nivolumab
- BIOLOGICAL enadenotucirev
Study Locations (6)
California
- City of Hope Comprehensive Cancer Center, 1500 E Duarte Str. - Duarte
- UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360 - Santa Monica
Arizona
- University of Arizona Cancer Center, 1515 North Campbell Ave. - Tucson
Indiana
- Horizon Oncology Research, 1345 Unity Place, Suite 365 - Lafayette
Michigan
- Henry Ford Hospital, 2799 West Grand Blvd. - Detroit
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2016-01-25 |
| Est. Completion | 2021-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02636036
The ClinicalTrials.gov registry entry for NCT02636036 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Akamis Bio, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which nivolumab is the first listed.
NCT02636036 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Indiana.
Frequently Asked Questions
What is clinical trial NCT02636036 about?
NCT02636036 is a clinical study titled "Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors". This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, SCCHN, escalation phase), not responding to standard therapy.
What is the current status of trial NCT02636036?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2016-01-25. Estimated completion is 2021-10-08.
What conditions does trial NCT02636036 study?
This clinical trial studies the following conditions: Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor.
What interventions are being tested in trial NCT02636036?
The interventions under investigation include: nivolumab (BIOLOGICAL), enadenotucirev (BIOLOGICAL).
Who is sponsoring clinical trial NCT02636036?
This trial is sponsored by Akamis Bio, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02636036 being conducted?
This trial has 6 study locations across Arizona, California, Indiana, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.